{
  "DMP.DE": {
    "city": "GrÃ¼nwald",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Dermapharm Holding SE",
    "market": "de_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "DERMAPHARM HLDG INH O.N.",
    "state": null,
    "summary": "Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three divisions: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, enzymes, dermatologics, systemic corticoids, women's healthcare, pain treatment, and ophthalmologics primarily under the Dekristol, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; food supplements under the HÃ¼bner brand; and Azedil, a nasal spray and eye drop product to treat acute hay fever symptoms. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in GrÃ¼nwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.",
    "website": "http://www.dermapharm.de",
    "zipcode": "82031"
  },
  "DMP.F": {
    "city": "GrÃ¼nwald",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Dermapharm Holding SE",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "DERMAPHARM HLDG INH O.N.",
    "state": null,
    "summary": "Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three divisions: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, enzymes, dermatologics, systemic corticoids, women's healthcare, pain treatment, and ophthalmologics primarily under the Dekristol, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; food supplements under the HÃ¼bner brand; and Azedil, a nasal spray and eye drop product to treat acute hay fever symptoms. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in GrÃ¼nwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.",
    "website": "http://www.dermapharm.de",
    "zipcode": "82031"
  },
  "EVOTF": {
    "city": "Hamburg",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Evotec SE",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "EVOTEC SE",
    "state": null,
    "summary": "Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services. Its EVT Innovate segment is involved in developing drug discovery projects, assets, and platforms. The company's portfolio of research and development programs include diabetes and diabetic complications, fibrosis, immunology, infectious and inflammatory diseases, kidney and liver diseases, oncological and rare diseases, pain, respiratory diseases, and women's health. Evotec SE was founded in 1993 and is headquartered in Hamburg, Germany.",
    "website": "http://www.evotec.com",
    "zipcode": "22419"
  },
  "EVT.DE": {
    "city": "Hamburg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Evotec SE",
    "market": "de_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "EVOTEC SE  INH O.N.",
    "state": null,
    "summary": "Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services. Its EVT Innovate segment is involved in developing drug discovery projects, assets, and platforms. The company's portfolio of research and development programs include diabetes and diabetic complications, fibrosis, immunology, infectious and inflammatory diseases, kidney and liver diseases, oncological and rare diseases, pain, respiratory diseases, and women's health. Evotec SE was founded in 1993 and is headquartered in Hamburg, Germany.",
    "website": "http://www.evotec.com",
    "zipcode": "22419"
  },
  "EVT.F": {
    "city": "Hamburg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Evotec SE",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "EVOTEC SE  INH O.N.",
    "state": null,
    "summary": "Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services. Its EVT Innovate segment is involved in developing drug discovery projects, assets, and platforms. The company's portfolio of research and development programs include diabetes and diabetic complications, fibrosis, immunology, infectious and inflammatory diseases, kidney and liver diseases, oncological and rare diseases, pain, respiratory diseases, and women's health. Evotec SE was founded in 1993 and is headquartered in Hamburg, Germany.",
    "website": "http://www.evotec.com",
    "zipcode": "22419"
  },
  "EVT.VI": {
    "city": "Hamburg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Evotec SE",
    "market": "at_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "EVOTEC SE",
    "state": null,
    "summary": "Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services. Its EVT Innovate segment is involved in developing drug discovery projects, assets, and platforms. The company's portfolio of research and development programs include diabetes and diabetic complications, fibrosis, immunology, infectious and inflammatory diseases, kidney and liver diseases, oncological and rare diseases, pain, respiratory diseases, and women's health. Evotec SE was founded in 1993 and is headquartered in Hamburg, Germany.",
    "website": "http://www.evotec.com",
    "zipcode": "22419"
  },
  "EVTA.F": {
    "city": "Hamburg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Evotec SE",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "EVOTEC SE ADR/2 O.N.",
    "state": null,
    "summary": "Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services. Its EVT Innovate segment is involved in developing drug discovery projects, assets, and platforms. The company's portfolio of research and development programs include diabetes and diabetic complications, fibrosis, immunology, infectious and inflammatory diseases, kidney and liver diseases, oncological and rare diseases, pain, respiratory diseases, and women's health. Evotec SE was founded in 1993 and is headquartered in Hamburg, Germany.",
    "website": "http://www.evotec.com",
    "zipcode": "22419"
  },
  "EVTCY": {
    "city": "Hamburg",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Evotec SE",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "EVOTEC SE",
    "state": null,
    "summary": "Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services. Its EVT Innovate segment is involved in developing drug discovery projects, assets, and platforms. The company's portfolio of research and development programs include diabetes and diabetic complications, fibrosis, immunology, infectious and inflammatory diseases, kidney and liver diseases, oncological and rare diseases, pain, respiratory diseases, and women's health. Evotec SE was founded in 1993 and is headquartered in Hamburg, Germany.",
    "website": "http://www.evotec.com",
    "zipcode": "22419"
  },
  "HAEK.DE": {
    "city": "SchÃ¶nefeld",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "HAEMATO AG",
    "market": "de_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "HAEMATO AG  INH O.N.",
    "state": null,
    "summary": "HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. The company distributes European import medicinal products; and manufactures and distributes its own generic medicinal products. It provides pharmaceuticals in the areas of oncology, HIV/AIDS, rheumatism, neurology, and cardiovascular diseases; and products for aesthetic treatments. The company also develops and commercializes pharmaceutical, medicinal, and medical engineering products for aesthetic surgery and cosmetic dermatology. It serves wholesalers and pharmacies, as well as doctors and hospitals. The company was founded in 1993 and is headquartered in SchÃ¶nefeld, Germany.",
    "website": "http://www.haemato.ag",
    "zipcode": "12529"
  },
  "HEMP.F": {
    "city": "Hamburg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Deutsche Cannabis AG",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "DT.CANNABIS AG  O.N.",
    "state": null,
    "summary": "Deutsche Cannabis AG engages in the acquisition, sale, and management of investments in cannabis industry primarily in Germany. It also focuses on the investment in the renewable energy sector, such as photovoltaics and cogeneration. The company was formerly known as F.A.M.E. AG and changed its name to Deutsche Cannabis AG in December 2014. Deutsche Cannabis AG was founded in 1999 and is based in Hamburg, Germany.",
    "website": "http://www.deutschecannabis.com",
    "zipcode": "22399"
  },
  "L3D.DE": {
    "city": "Munich",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "SynBiotic SE",
    "market": "de_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SYNBIOTIC SE  INH O.N.",
    "state": null,
    "summary": "SynBiotic SE engages in the development of medicines and over-the-counter wellness products based on cannabinoids. It focuses on synthetic production of cannabinoids, drug development, nutritional supplements, and cosmetic products. The company was formerly known as Ledgertech SE and changed its name to Ledgertech SE. SynBiotic SE based in Munich, Germany.",
    "website": "http://www.synbiotic.com",
    "zipcode": "81667"
  },
  "L3D.DU": {
    "city": "Munich",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "DUS",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "SynBiotic SE",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SYNBIOTIC SE  INH O.N.",
    "state": null,
    "summary": "SynBiotic SE engages in the development of medicines and over-the-counter wellness products based on cannabinoids. It focuses on synthetic production of cannabinoids, drug development, nutritional supplements, and cosmetic products. The company was formerly known as Ledgertech SE and changed its name to Ledgertech SE. SynBiotic SE based in Munich, Germany.",
    "website": "http://www.synbiotic.com",
    "zipcode": "81667"
  },
  "L3D.F": {
    "city": "Munich",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "SynBiotic SE",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SYNBIOTIC SE  INH O.N.",
    "state": null,
    "summary": "SynBiotic SE engages in the development of medicines and over-the-counter wellness products based on cannabinoids. It focuses on synthetic production of cannabinoids, drug development, nutritional supplements, and cosmetic products. The company was formerly known as Ledgertech SE and changed its name to Ledgertech SE. SynBiotic SE based in Munich, Germany.",
    "website": "http://www.synbiotic.com",
    "zipcode": "81667"
  },
  "MKGAF": {
    "city": "Darmstadt",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MERCK Kommanditgesellschaft auf Aktien",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "MERCK KGAA",
    "state": null,
    "summary": "MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat oncology, immuno-oncology, neurology, immunology, fertility, and endocrinology, as well as general medicines for diabetes, cardiovascular, thyroid, and other diseases. The company also provides life science products and services, including research, process, and applied solution. In addition, it offers specialty chemicals for semiconductor, liquid crystals, organic light-emitting diodes, effect pigments, automotive, and functional solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Novartis AG and Vera Therapeutics, Inc.; and collaboration with F-star Delta Ltd. and Artios Pharma Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft. MERCK Kommanditgesellschaft auf Aktien operates as a subsidiary of E. Merck KG.",
    "website": "http://www.merckgroup.com",
    "zipcode": "64293"
  },
  "MKKGY": {
    "city": "Darmstadt",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MERCK Kommanditgesellschaft auf Aktien",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "MERCK KGAA",
    "state": null,
    "summary": "MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat oncology, immuno-oncology, neurology, immunology, fertility, and endocrinology, as well as general medicines for diabetes, cardiovascular, thyroid, and other diseases. The company also provides life science products and services, including research, process, and applied solution. In addition, it offers specialty chemicals for semiconductor, liquid crystals, organic light-emitting diodes, effect pigments, automotive, and functional solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Novartis AG and Vera Therapeutics, Inc.; and collaboration with F-star Delta Ltd. and Artios Pharma Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft. MERCK Kommanditgesellschaft auf Aktien operates as a subsidiary of E. Merck KG.",
    "website": "http://www.merckgroup.com",
    "zipcode": "64293"
  },
  "MRCK.VI": {
    "city": "Darmstadt",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MERCK Kommanditgesellschaft auf Aktien",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "MERCK KGAA",
    "state": null,
    "summary": "MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat oncology, immuno-oncology, neurology, immunology, fertility, and endocrinology, as well as general medicines for diabetes, cardiovascular, thyroid, and other diseases. The company also provides life science products and services, including research, process, and applied solution. In addition, it offers specialty chemicals for semiconductor, liquid crystals, organic light-emitting diodes, effect pigments, automotive, and functional solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Novartis AG and Vera Therapeutics, Inc.; and collaboration with F-star Delta Ltd. and Artios Pharma Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft. MERCK Kommanditgesellschaft auf Aktien operates as a subsidiary of E. Merck KG.",
    "website": "http://www.merckgroup.com",
    "zipcode": "64293"
  },
  "MRK.DE": {
    "city": "Darmstadt",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MERCK Kommanditgesellschaft auf Aktien",
    "market": "de_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "MERCK KGAA O.N.",
    "state": null,
    "summary": "MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat oncology, immuno-oncology, neurology, immunology, fertility, and endocrinology, as well as general medicines for diabetes, cardiovascular, thyroid, and other diseases. The company also provides life science products and services, including research, process, and applied solution. In addition, it offers specialty chemicals for semiconductor, liquid crystals, organic light-emitting diodes, effect pigments, automotive, and functional solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Novartis AG and Vera Therapeutics, Inc.; and collaboration with F-star Delta Ltd. and Artios Pharma Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft. MERCK Kommanditgesellschaft auf Aktien operates as a subsidiary of E. Merck KG.",
    "website": "http://www.merckgroup.com",
    "zipcode": "64293"
  },
  "MRK.F": {
    "city": "Darmstadt",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MERCK Kommanditgesellschaft auf Aktien",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "MERCK KGAA O.N.",
    "state": null,
    "summary": "MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat oncology, immuno-oncology, neurology, immunology, fertility, and endocrinology, as well as general medicines for diabetes, cardiovascular, thyroid, and other diseases. The company also provides life science products and services, including research, process, and applied solution. In addition, it offers specialty chemicals for semiconductor, liquid crystals, organic light-emitting diodes, effect pigments, automotive, and functional solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Novartis AG and Vera Therapeutics, Inc.; and collaboration with F-star Delta Ltd. and Artios Pharma Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft. MERCK Kommanditgesellschaft auf Aktien operates as a subsidiary of E. Merck KG.",
    "website": "http://www.merckgroup.com",
    "zipcode": "64293"
  },
  "MRK.MI": {
    "city": "Darmstadt",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "MIL",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MERCK Kommanditgesellschaft auf Aktien",
    "market": "it_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "MERCK",
    "state": null,
    "summary": "MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat oncology, immuno-oncology, neurology, immunology, fertility, and endocrinology, as well as general medicines for diabetes, cardiovascular, thyroid, and other diseases. The company also provides life science products and services, including research, process, and applied solution. In addition, it offers specialty chemicals for semiconductor, liquid crystals, organic light-emitting diodes, effect pigments, automotive, and functional solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Novartis AG and Vera Therapeutics, Inc.; and collaboration with F-star Delta Ltd. and Artios Pharma Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft. MERCK Kommanditgesellschaft auf Aktien operates as a subsidiary of E. Merck KG.",
    "website": "http://www.merckgroup.com",
    "zipcode": "64293"
  },
  "MRKC.SG": {
    "city": "Darmstadt",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "STU",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MERCK Kommanditgesellschaft auf Aktien",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "Merck KGaA Nam.-Akt.(Sp.ADRs) 1",
    "state": null,
    "summary": "MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat oncology, immuno-oncology, neurology, immunology, fertility, and endocrinology, as well as general medicines for diabetes, cardiovascular, thyroid, and other diseases. The company also provides life science products and services, including research, process, and applied solution. In addition, it offers specialty chemicals for semiconductor, liquid crystals, organic light-emitting diodes, effect pigments, automotive, and functional solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Novartis AG and Vera Therapeutics, Inc.; and collaboration with F-star Delta Ltd. and Artios Pharma Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft. MERCK Kommanditgesellschaft auf Aktien operates as a subsidiary of E. Merck KG.",
    "website": "http://www.merckgroup.com",
    "zipcode": "64293"
  },
  "PSG.DE": {
    "city": "GrÃ¤felfing",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "PharmaSGP Holding SE",
    "market": "de_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PHARMASGP HOLDING SE O.N.",
    "state": null,
    "summary": "PharmaSGP Holding SE manufactures non-chemical, over-the-counter drugs, and other healthcare products. The company's pharmaceutical products include RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Fulminan, a beauty drink for problems in areas such as eye area, buttocks, or thighs; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo. It also offers products for the treatment of chronic indications, including pain and other age-related ailments. The company sells its products through pharmacies and wholesalers. It exports its products to European countries comprising Austria, Italy, Belgium, and Spain. PharmaSGP Holding SE was founded in 2012 and is based in GrÃ¤felfing, Germany.",
    "website": "http://pharmasgp.com",
    "zipcode": "82166"
  },
  "PSG.F": {
    "city": "GrÃ¤felfing",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "PharmaSGP Holding SE",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PHARMASGP HOLDING SE O.N.",
    "state": null,
    "summary": "PharmaSGP Holding SE manufactures non-chemical, over-the-counter drugs, and other healthcare products. The company's pharmaceutical products include RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Fulminan, a beauty drink for problems in areas such as eye area, buttocks, or thighs; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo. It also offers products for the treatment of chronic indications, including pain and other age-related ailments. The company sells its products through pharmacies and wholesalers. It exports its products to European countries comprising Austria, Italy, Belgium, and Spain. PharmaSGP Holding SE was founded in 2012 and is based in GrÃ¤felfing, Germany.",
    "website": "http://pharmasgp.com",
    "zipcode": "82166"
  }
}
